LM-364 / Sino Biopharm, LaNova Medicines Limited - LARVOL DELTA

A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=90 | Not yet recruiting | Sponsor: LaNova Medicines Limited

First-in-human • New P1/2 trial • Oncology • Solid Tumor

Preclinical evaluation of LM-364TME: A next-generation anti-Nectin4 ADC with promising efficacy and reduced toxicity (AACR 2026) - "The clinical success of enfortumab vedotin valudated Nectin-4 as a therapeutic target; however, dose-limiting skin rash and neuropathy arise from on target, off-tumor toxicity due to low Nectin-4 epxression in nomal tissues. LM-364TME is an ANP-dependent, conditionally active anti-Nectin-4-ADC that demonstrates potent and selective antitumor activity with favorable safety profile in preclinical models. These data support LM-364TME as a promising next-generation Nectin-4-targeted therapy with the potential to improve the therapeutic index of this class.Keywords: Nectin-4, antibody-drug conjugate, LM-364TME, solid tumorsDisclosure: The study was funded by LaNova Medicines Limited, China."

ADC • Preclinical • Cervical Cancer • Esophageal Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • Urothelial Cancer • NECTIN4